Evaluation of MicroScan Neg Combo Panel Type 21 to Detect ESBL
Original article PDF Yoon Hee Kang, M.D., Soo Jin Choi, M.D., Sang Hyun Hwang, M.D., Young Wook Cho, M.D., Duck-Hee Kim, M.T.*, Mi-Na Kim, M.D. and Chik Hyun Pai, M.D. Department of Clinical Pathology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea Corresponding to Mi-Na Kim Ann Clin Microbiol 1999;2(2):158-166.Copyright © Korean Society of Clinical Microbiology. Abstract Background: Escherichia coli and Klebsiella pneumoniae resistant to 3rd generation cephalosporin have been reported with increasing frequency in tertiary-care hospital in Korea. MicroScan Neg Combo Panel Type 21 (Type 21) contains a 1 µg/mL cepfoxodime (POD) in addition to other screen wells containing ceftazidime, cefotaxime, ceftriaxone, and aztreonam, which are designed for detecting extended-spectrum β-lactamase (ESBL)-producing E. coli and Klebsiella species. We evaluated the Type 21 panel for its ability to detect ESBL. Methods: From November to December in 1998, 496 E. coli and 326 K. pneumoniae strains isolated from clinical specimens were tested with Type 21 panel. The isolates